Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Medicinal Chemistry.Register Now
The Medicinal Chemistry Roundtable Discussions Strategy Meeting are for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.
Those who do not qualify for VIP passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Chief Scientific Officer, Head of Chemistry, Eli Lilly and Company
Chief Scientific Officer, Bioversys AG
Senior Vice President, Peptides, Ipsen
Vice President, Global Head of Medicinal Chemistry, Merck
Vice President, Research, LEO Pharma
Global Head, External Science & Drug Discovery, Global Discovery Chemistry, Novartis
Global Head Discovery Safety, Drug Safety & Metabolism, Astrazeneca
Director, Medicinal Chemistry, Boehringer-Ingelheim
In 2002 joined Boehringer Ingelheim in Vienna to build up the MedChem Facilities for Oncology research. Experience in drug discovery from early stage to clinical candidates. In 2013 appointed Director at Boehringer Ingelheim in Vienna taking responsibility for drug discovery strategy, MedChem and organic synthesis.
Senior Vice President, Discovery Technologies
Klaus Urbahns has more than 20 years of experience in the biopharmaceutical industry. He is Senior Vice President, Head of the Discovery Technology Platform at MerckSerono with laboratories in the US, Israel and Germany. His team’s role is to generate small molecule drug candidates and therapeutic proteins. Prior to joining Merck, Klaus served at AstraZeneca in the UK and Sweden. He started his professional career at Bayer, holding positions in Germany and Japan. Klaus is member of the advisory board of the Lead Discovery Center (LDC) and the Medicines for Malaria Venture (MMV). Klaus studied chemistry at the universities of Kiel, Freiburg and Frankfurt.
Vice President, Discovery Research Site Head, Austria
Darryl McConnell is currently Research Site Head and Head of Medicinal Chemistry at Boehringer-Ingelheim Regional Centre Vienna, Austria where the main research focus is oncology. Darryl commenced his career with Boehringer-Ingelheim in 2002 as a Research Laboratory Head and is in his current role since 2015.
Prior to this Darryl has worked for Intervet in Vienna from 2001, for Biota Holdings Ltd in Melbourne, Australia from 1999 in the area of respiratory viruses and Chiron Technologies in Melbourne from 1997.
Darryl McConnell received his Bachelor of Science with First Class Honours in 1991 with Professor John Elix at the Australian National University in Canberra. He performed his PhD at the University of New South Wales in Sydney with Professor David Black for which he was awarded the Cornforth Medal for the best chemistry PhD thesis in Australia for that year. Following this he performed a 2 year Postdoctoral study at the University of Sydney with Professor Leslie Field in organometallic chemistry.
Darryl’s interest lie in the areas of cancer cell directed and immune cell directed therapies for cancer as well as protein crystallography and protein NMR, fragment based and structure based drug discovery, drug discovery software development, agile methods in drug discovery and natural product inspired medicinal chemistry.
Senior Vice President, Chemistry
Jean Kim is a Senior V.P. of Chemistry at Kadmon where she currently leads the discovery of small molecule therapeutic agents for Oncology, Autoimmunity, and Anti-infective diseases. She directed numerous research programs at Merck and Wyeth Laboratories and has worked in the field of Medicinal Chemistry Research for over 20-years, towards finding therapies for Metabolic Syndrome and Diabetes, and Neurological disorders. Jean is a co-inventor of Nemonoxacin, an antibiotic marketed for the treatment of community-acquired pneumonia (CAP). Jean received her Ph.D. in organic chemistry from University of Illinois, at Champaign-Urbana, and completed post-doctoral research in University of Basel, Switzerland after receiving her B.S. in chemistry from Cornell University.
Return on Investment, Medicinal Chemistry Strategy Meeting Europe 2016
Radisson Blu Hotel
Rondellstrasse, 8058 Zürich